Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.47
- Piotroski Score 4.00
- Grade Market Perform
- Symbol (EHAB)
- Company Enhabit, Inc.
- Price $8.10
- Changes Percentage (3.25%)
- Change $0.26
- Day Low $7.81
- Day High $8.15
- Year High $12.61
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $10.25
- High Stock Price Target $12.00
- Low Stock Price Target $8.50
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.65
- Trailing P/E Ratio -5.57
- Forward P/E Ratio -5.57
- P/E Growth -5.57
- Net Income $-80,500,000
Income Statement
Quarterly
Annual
Latest News of EHAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Kodai Senga's injury rehab taking next step with Mets optimistic for...
Kodai Senga's rehab progress includes facing hitters in live batting practice. Mets remain cautiously optimistic about his return this season, considering various factors before making a decision on h...
By New York Post | 11 hours ago -
Tiger Woods Breaks Silence After Back Surgery - 'Tackling This Rehab'
Tiger Woods underwent successful back surgery, aiming to alleviate pain and spasms. Despite past health challenges, Woods remains determined to return to golf after rehab. His recovery journey include...
By Newsweek | 18 hours ago -
NewYork-Presbyterian/Columbia wants to shut down its rehab unit. Here's why.
NewYork-Presbyterian/Columbia plans to convert its Acute Inpatient Rehab Unit to inpatient beds in the emergency department to address overcrowding and improve patient care. Despite concerns from the ...
By CBS News | 6 days ago
